Toleranzia

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW.

Toleranzia AB (“Toleranzia” or the “Company”) today announces the outcome of the exercise of warrants of series TO4 (“TO4”), which were issued in connection with the Company's rights issue of units during the second quarter of 2023. The summary shows that a total of 73,891,131 TO4, corresponding to approximately 85 percent of the total number of TO4 issued, were exercised for subscription of 73,891,131 new shares. As communicated by way of press release on 28 August 2024, the Company received subscription commitments corresponding to approximately 71.14 percent of the total issue proceeds that the Company could raise through the utilisation of TO4. Through the utilisation of TO4, Toleranzia receives approximately SEK 37 million before issue related costs.
 
Background
The exercise period for TO4 ran from 7 October 2024 up to and including 21 October 2024. The subscription price per share upon exercise of TO4 amounted to SEK 0.50.
 
Interim shares
Exercised TO4 have been replaced with interim shares (IA) pending registration with the Swedish Companies Registration Office. The conversion of interim shares to shares is expected to take place within approximately two (2) weeks.
 
Number of shares, share capital and dilution
Through the utilisation of TO4, the share capital will increase by SEK 9,236,391.375 to SEK 33,870,250.750 through the issue of 73,891,131 shares, meaning that the total number of outstanding shares in the Company will increase from 197,070,875 to 270,962,006. The dilution upon utilisation of TO4 amounts to approximately 27.3 percent.
 
Comment from Charlotte Fribert, CEO
We are very pleased with the good outcome of the exercise of the warrants of series TO4. We see the extent of participation as proof of a high level of confidence in the Company. With the capital raised, we strengthen the financial base for the continued development of TOL2, a new unique treatment for patients with myasthenia gravis. I would like to extend a big thank you to existing and new shareholders in Toleranzia who participated in the warrant program for their willingness to join the company's exciting journey towards its first drug in the field of rare autoimmune diseases.
 
Advisors
Zonda Partners AB is acting as financial advisor and Eversheds Sutherland Advokatbyrå AB is acting as legal advisor to Toleranzia in relation to utilisation of the TO4. Nordic Issuing is acting as issuing agent in connection with the utilisation of TO4.
 
For further information, please contact
Charlotte Fribert - CEO, Toleranzia AB
Tel: +46 763 19 98 98
E-mail: charlotte.fribert@toleranzia.com

About Toleranzia AB (publ)
Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.